Matching patients with drugs: Triumphs and challenges

Personalized Medicine

Volumn 3, Issue 3, 2006, Pages 335-344

  Waring, Paul M ^a  

^a GENENTECH INC   (United States)

Author keywords

Biomarkers; Cetuximab; Diagnostics; EGFR; Erlotinib; Gefitinib; HER2; Imatinib; Personalized medicine; Predictive; Traztuzumab

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; RITUXIMAB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG APPROVAL; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH ECONOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION PROCESS;

EID: 33747258960     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.3.335     Document Type: Article

References (31)

1. Personalised medicine: hopes and realities. The Royal Society (2005).
2. Drug-Diagnostic Co-Development Concept Paper, Draft. Food and Drug Administration (2005).
3. Slamon DJ, Leyland-Jones B Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancers that overexpressed HER2. N. Engl. J. Med. 344, 783-792 (2001).
4. Mass RD, Press MF, Anderson S et al.: Evaluation of clinical outcome according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6(3), 240-246 (2005).
5. Paik S, Bryant J, Tan-Chiu E et al.: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 94(11), 852-854 (2002).
6. Roche PC, Suman VJ, Jenkins RB et al.: Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J. Nat. Cancer Inst: 94(11), 855-857 (2002).
7. Press MF, Sauter G, Bernstein L et al.: Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11(18), 6598-6607 (2005).
8. Saitz LB, Meropol NJ, Loehrer PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expressed the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
9. Cunningham DM, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximan plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
10. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications of a standardized scoring system. Cancer 92, 1331-1346 (2001).
11. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal anatibodies. J. Clin. Oncol. 22(23), 4772-4778 (2004).
12. Chung KY, Shia J, Kemeny NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1180 (2005).
13. Tsao M-S, Sakurada A, Cutz J-C et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
14. Eberhard DA, Johnson BE, Amler LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with Erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
15. Bell DW, Lynch TJ, Haserlat SM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23(31), 8081-8092 (2005).
16. Kris MG, Natale RB, Herbst RS et al.: Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290(16), 2149-2158 (2003).
17. Fukuoka M, Yano S, Giaccone G et al.: Multi-instititional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol 2l, 2237-2246 (2003).
18. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI0774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
19. Paez G, Janne J, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
20. Lynch T, Bell D, Sordella R et al.: Activating mutations in epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
21. Cappuzzo F, Magrini E, Cereoli GL et al.: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small cell lung cancer. J. Natl. Cancer Inst. 96, 1133-1141 (2004).
22. Sordella R, Bell DW, Haber DA et al.: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
23. Capuzzo F, Hirsch FR, Rossi E et al.: Epidermal growth factor receptor and protein and gefitinib sensitivity in non-small cell lung cancer. J. Natl Cancer Inst. 97(9), 643-655 (2005).
24. Perez-Soler R, Chachoua A, Hammond L et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
25. Parra HS, Cavina R, Latteri F et al.: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa, ZD1839) in non-small cell lung cancer. Br. J. Cancer 91, 208-212 (2004).
26. Hirsch FR, Bunn PA Jr: Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J. Clin. Oncol 23, 9044-9047 (2005).
27. Yauch RL, Januario, T, Eberhard DA et al.: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11(24), 8688-8698 (2005).
28. Tomson S, Buck E, Petti F et al.: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65(20), 9455-9462 (2005).
29. Witta SE, Gemmill RM, Hirsch FR et al.: Restoring E-cadherin expression increases sensitivity of epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 66(2), 944-950 (2006).
30. Bremnes RM, Gabrielson RVE, Hirsch FR et al.: High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small cell lung cancer. J. Clin Oncol 20, 2417-2428 (2002).
31. Heinrich MC, Blanke CD, Corless CL et al.: Small molecule inhibitors of protein kinases in the treatment of human cancer. In: Cancer Mediane 6th Ed. Bast RC, Kufe DW, Pollack RE et al. (Eds), BC Decker Inc., Hamilton, Canada, 811-821 (2003).